Patents by Inventor Xiaozhang Zheng

Xiaozhang Zheng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IRAK DEGRADERS AND USES THEREOF
    Publication number: 20250121073
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: October 10, 2024
    Publication date: April 17, 2025
    Inventors: Nello Mainolfi, Nan Ji, Matthew M. Weiss, Xiaozhang Zheng, Yi Zhang, Paul R. Fleming, Xiao Zhu
  • CDK2 DEGRADERS AND USES THEREOF
    Publication number: 20250114461
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: June 28, 2024
    Publication date: April 10, 2025
    Inventors: Xiaozhang Zheng, Yi Zhang, Robert Aversa, Xiao Zhu, Philip Collier
  • SMARCA DEGRADERS AND USES THEREOF
    Publication number: 20250109138
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: December 9, 2021
    Publication date: April 3, 2025
    Inventors: Yi ZHANG, Xiaozhang ZHENG, Xiao ZHU
  • 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
    Patent number: 12264137
    Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
    Type: Grant
    Filed: March 10, 2022
    Date of Patent: April 1, 2025
    Assignee: VALO HEALTH, INC.
    Inventors: Xiaozhang Zheng, Pui Yee Ng, Bingsong Han, Jennifer R. Thomason, Mary-Margaret Zablocki, Cuixian Liu, Aleksandra Rudnitskaya, David R. Lancia, Jr., David S. Millan, Matthew W. Martin
  • IRAK degraders and uses thereof
    Patent number: 12258341
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: July 19, 2023
    Date of Patent: March 25, 2025
    Assignee: Kymera Therapeutics, Inc.
    Inventors: Nello Mainolfi, Nan Ji, Arthur F. Kluge, Matthew M. Weiss, Yi Zhang, Xiaozhang Zheng
  • IRAK DEGRADERS AND USES THEREOF
    Publication number: 20250059164
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: June 23, 2024
    Publication date: February 20, 2025
    Inventors: Xiaozhang ZHENG, Nello Mainolfi, Matthew M. Weiss
  • 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors
    Patent number: 12213969
    Abstract: The present invention is directed to inhibitors of histone deacetylases (HDACs) such as HDAC6, and their use in the treatment of diseases such as cell proliferative diseases (e.g., cancer), neurological (e.g., neurodegenerative disease or neurodevelopmental disease), inflammatory or autoimmune disease, infection, metabolic disease, hematologic disease, or cardiovascular disease.
    Type: Grant
    Filed: June 29, 2023
    Date of Patent: February 4, 2025
    Assignee: VALO HEALTH, INC.
    Inventors: Xiaozhang Zheng, Pui Yee Ng, Mary-Margaret Zablocki
  • IRAK DEGRADERS AND USES THEREOF
    Publication number: 20250011325
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: August 9, 2024
    Publication date: January 9, 2025
    Inventors: Nello Mainolfi, Christopher De Savi, Matthew M. Weiss, Xiao Zhu, Xiaozhang Zheng, Bruce C. Follows
  • MDM2 DEGRADERS AND USES THEREOF
    Publication number: 20240424110
    Abstract: The present invention relates to compounds and methods useful for the modulation of mouse double minute 2 homolog (“MDM2”) protein via ubiquitination and/or degradation by compounds according to the present invention.
    Type: Application
    Filed: March 19, 2021
    Publication date: December 26, 2024
    Inventors: Nan JI, Matthew M. WEISS, Xiaozhang ZHENG, Xiao ZHU
  • PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS
    Publication number: 20240391922
    Abstract: The disclosure relates to modulating pyruvate kinase and provides novel chemical compounds useful as activators of PKR, as well as various uses of these compounds. PKR activating compounds are useful in the treatment of diseases and disorders associated with PKR and/or PKM2, such as pyruvate kinase deficiency (PKD), sickle cell disease (SCD), and thalassemia.
    Type: Application
    Filed: July 17, 2024
    Publication date: November 28, 2024
    Inventors: Anna Ericsson, Neal Green, Gary Gustafson, Bingsong Han, David R. Lancia, JR., Lorna Mitchell, David Richard, Tatiana Shelekhin, Chase C. Smith, Zhongguo Wang, Xiaozhang Zheng
  • IRAK degraders and uses thereof
    Patent number: 12150995
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: December 30, 2021
    Date of Patent: November 26, 2024
    Assignee: Kymera Therapeutics, Inc.
    Inventors: Nello Mainolfi, Nan Ji, Matthew M. Weiss, Xiaozhang Zheng, Yi Zhang, Paul R. Fleming, Xiao Zhu
  • Activating pyruvate kinase R
    Patent number: 12122778
    Abstract: The disclosure provides novel chemical compounds useful as activators of PKR. PKR activating compounds are useful in the treatment of disease and disorders associated with modulation of PKR and/or PKM2, such as pyruvate kinase deficiency (PKD).
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: October 22, 2024
    Assignee: Novo Nordisk Health Care AG
    Inventors: Xiaozhang Zheng, Anna Ericsson, Neal Green, Gary Gustafson, David R. Lancia, Jr., Jian Lin, Lorna Mitchell, David Richard, Tatiana Shelekhin
  • SMARCA DEGRADERS AND USES THEREOF
    Publication number: 20240343724
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: December 9, 2021
    Publication date: October 17, 2024
    Inventors: Yi ZHANG, Xiaozhang ZHENG, Xiao ZHU
  • CDK2 degraders and uses thereof
    Patent number: 12097261
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: May 6, 2022
    Date of Patent: September 24, 2024
    Assignee: Kymera Therapeutics, Inc.
    Inventors: Xiaozhang Zheng, Yi Zhang, Robert Aversa, Xiao Zhu, Philip Collier
  • IRAK degraders and uses thereof
    Patent number: 12091411
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: January 31, 2023
    Date of Patent: September 17, 2024
    Assignee: Kymera Therapeutics, Inc.
    Inventors: Nello Mainolfi, Chris De Savi, Matthew M. Weiss, Xiao Zhu, Xiaozhang Zheng, Bruce C. Follows
  • STAT DEGRADERS AND USES THEREOF
    Publication number: 20240293423
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: October 7, 2021
    Publication date: September 5, 2024
    Inventors: Bin YANG, Xiaozhang ZHENG, Xiao ZHU
  • Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators
    Patent number: 12071440
    Abstract: The disclosure relates to modulating pyruvate kinase and provides novel chemical compounds useful as activators of PKR, as well as various uses of these compounds. PKR activating compounds are useful in the treatment of diseases and disorders associated with PKR and/or PKM2, such as pyruvate kinase deficiency (PKD), sickle cell disease (SCD), and thalassemia.
    Type: Grant
    Filed: March 21, 2023
    Date of Patent: August 27, 2024
    Assignee: Novo Nordisk Health Care AG
    Inventors: Anna Ericsson, Neal Green, Gary Gustafson, Bingsong Han, David R. Lancia, Jr., Lorna Mitchell, David Richard, Tatiana Shelekhin, Chase C. Smith, Zhongguo Wang, Xiaozhang Zheng
  • Treating sickle cell disease with a pyruvate kinase R activating compound
    Patent number: 12053458
    Abstract: Compounds that activate pyruvate kinase R can be used for the treatment of sickle cell disease (SCD). Methods and compositions for the treatment of SCD are provided herein, including a therapeutic compound designated as Compound 1.
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: August 6, 2024
    Assignee: Novo Nordisk Health Care AG
    Inventors: Anna Ericsson, Neal Green, Gary Gustafson, David R. Lancia, Jr., Bingsong Han, Lorna Mitchell, David Richard, Zhongguo Wang, Tatiana Shelekhin, Chase C. Smith, Xiaozhang Zheng
  • IRAK DEGRADERS AND USES THEREOF
    Publication number: 20240239777
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: July 19, 2023
    Publication date: July 18, 2024
    Inventors: Nello Mainolfi, Nan Ji, Arthur F. Kluge, Matthew M. Weiss, Yi Zhang, Xiaozhang Zheng
  • CDK2 DEGRADERS AND USES THEREOF
    Publication number: 20240173419
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: August 21, 2023
    Publication date: May 30, 2024
    Inventors: Philip COLLIER, Xiaozhang ZHENG, Xiao ZHU, Melissa FORD, Matthew M. WEISS, Robert AVERSA, Lewis Dale PENNINGTON, Eamon COMER, Kiran Vijayakumari MAHASENAN, Yi ZHANG